Asthma

Lungs
#Asthma #AstraZeneca #European Commission #European Medicines Agency

EC approves first triple-combination therapy for asthma maintenance

AstraZeneca’s fixed-dose triple-combination Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate or BGF) has been approved in the European Union (EU) as a maintenance treatment for asthma.  It is approved in patients 12 years of age and older who are not adequately controlled by a combination of a medium dose… Read More

#News #Regulatory

Asthma inhaler
#Asthma #AstraZeneca #Committee for Medicinal Products for Human Use #European Medicines Agency

Asthma drug Trixeo recommended for approval in the EU

AstraZeneca’s fixed-dose triple-combination Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) has been recommended for approval in the EU for the maintenance treatment of asthma in patients 12 years of age and older.  It is recommended in patients who are not adequately controlled by a combination of a medium… Read More

#News #Regulatory

Woman using an asthma inhaler
#Asthma #AstraZeneca #FDA

FDA approves first asthma triple therapy in US

The US Food and Drug Administration (FDA) has approved the first and only triple therapy for patients 12 years and older with asthma.  AstraZeneca’s fixed-dose triple-combination therapy Breztri Aerosphere has been approved in the US for the maintenance treatment of asthma in adult and paediatric patients 12 years of age… Read More

#News #Regulatory

Asthma inhaler
#Asthma #Clinical trial

Apogee to advance potential best-in-class asthma treatment 

Biotechnology company Apogee Therapeutics has shared positive data for its potential best-in-class treatment for mild-to-moderate asthma.  Zumilokibart (APG77) was assessed in a Phase Ib double-blind, placebo-controlled trial of 19 adult patients with mild-to-moderate asthma. Results show the treatment was well-tolerated and offered a robust and durable suppression of FeNO, a biomarker… Read More

#News

Close up of vaccine syringe
#Asthma #Cold Urticaria #European Commission

Omlyclo set for line extension after EC approval 

The European Commission (EC) has granted a line extension in the European Union for Omlyclo (omalizumab), Europe’s first and only omalizumab biosimilar.  The EC approved Omlyclo 300mg/2ml prefilled syringe, following approval for 75mg/0.5ml and 150mg/1ml solutions in May 2024.  Omlyclo is indicated for the treatment of patients with allergic asthma, chronic… Read More

#News #Regulatory

Nasal spray
#Asthma #EMA

Tezpire recommended in EU to treat chronic rhinosinusitis

AstraZeneca and Amgen’s drug Tezspire (tezepelumab) has been recommended for approval in the European Union for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP).   The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on… Read More

#News

Business financing
#Asthma #Financing #Immunology #Monoclonal antibodies #Windward Bio

Windward Bio launches with $200 million

Windward Bio, a clinical-stage, drug development company focused on advanced immunological diseases, has announced its official launch.   OrbiMed, Novo Holdings, and Blue Owl Healthcare Opportunities lead the Series A financing of $200 million, with the co-investment of SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan… Read More

#Business & Investment #News #Start-up Zone

Woman reaches for inhaler
#Asthma #AstraZeneca #King's College London #Phase II trial

First new treatment for asthma attacks in 50 years

An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30%, according to a UK study.  The findings, published in The Lancet Respiratory Medicine, could… Read More

#News #Trending News

#Asthma #Cell sequencing #Drug discovery #Drug targets #Immunogenomics #Meet the Researcher

Meet the researcher: Timothy Hinks

DDW’s Megan Thomas talks to Professor Timothy Hinks, Associate Professor in Respiratory Immunology, Nuffield Department of Medicine. MT: Can you tell us what you do and what you’re working on at the moment? TH: I’m a clinician scientist, which I think is the best job in the world. Read More

#Exclusive Content

Biologic drugs
#Asthma #Biologics #Eczema #Glen Clova Scientific #Start-ups #University of Dundee

Improving the standard of biological drugs

DDW Editor Reece Armstrong speaks to Dr Steven Powell, co-founder of Glen Clova Scientific (GCS), about the company’s approach of using virus-like particles (VLPs) to treat conditions such as eczema and asthma, and what the current market looks like for this therapy area. Spun-out of the Univeristy of Dundee in… Read More

#Exclusive Content #Start-up Zone

Woman using an asthma inhaler
#Asthma #CAR-T #Cell therapy #China #Preclinical investigations

Researchers push asthma into remission with one dose of CAR-T

A single dose of long-lived chimeric antigen receptor (CAR)-T therapy led to sustained repression of lung inflammation and alleviation of asthmatic symptoms in a new study. The paper, ‘A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice’, was… Read More

#Editor's Choice #News

Woman reaches for inhaler
#Asthma #Bispecific Antibodies #Innovent #Phase I trial

Humanised bispecific antibody for asthma enters Phase I trial

Biopharmaceutical company Innovent Biologics has launched the first-in-human (FIH) Phase I clinical trial of IBI3002, a novel bispecific antibody targeting Interleukin 4 receptor α (IL-4Rα) and thymic stromal lymphopoietin (TSLP). The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of IBI3002 in healthy participants and… Read More

#News

GSK offices
#Asthma #GSK #Mergers and acquisitions #Monoclonal antibodies #Respiratory

GSK expands respiratory pipeline with Aiolos Bio acquisition

GSK is to acquire Aiolos Bio for a $1 billion upfront payment and up to $400 million in regulatory milestone payments. The acquisition includes Aiolos’ AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter Phase II clinical development for asthma, with… Read More

#Business & Investment #News

Asthma inhaler
#Asthma #AstraZeneca #Clinical trial #National Institute for Health and Care Excellence (NICE) #NHS England

Add-on treatment for severe uncontrolled asthma approved 

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending AstraZeneca’s Tezspire (tezepelumab).  The drug is approved for use within NHS England and NHS Wales and as add-on maintenance therapy in adult and adolescent patients, 12 years and older, with severe asthma… Read More

#News

Woman using an asthma inhaler
#Asthma #AstraZeneca #Avillion #FDA #Phase III trial #United States

FDA approves first rescue medication to manage asthma inflammation

Airsupra (albuterol/budesonide) has been approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older.  Airsupra is a pressurised metered-dose inhaler (pMDI), fixed-dose combination of albuterol, a short-acting beta2-agonist (SABA),… Read More

#News #Regulatory

Asthma inhaler
#Asthma #Biologics

First and only biologic approved in the EU in patients with severe asthma 

AstraZeneca’s Tezspire (tezepelumab) has been approved in the European Union as an add-on maintenance treatment in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product.  The approval by the European Commission was based on results… Read More

#News